NASDAQ:DOXAmdocs Stock Price, Forecast & News

Amdocs' stock was trading at $61.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DOX stock has increased by 1.9% and is now trading at $62.58.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amdocs.

Amdocs is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Amdocs.

Amdocs will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amdocs Limited (NASDAQ:DOX) posted its quarterly earnings results on Thursday, May, 7th. The technology company reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.02. The technology company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.04 billion. Amdocs had a net margin of 11.98% and a return on equity of 16.03%. The company's revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.06 EPS.
View Amdocs' earnings history.

Amdocs declared a quarterly dividend on Thursday, May 7th. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.327 per share on Friday, July 24th. This represents a $1.31 annualized dividend and a yield of 2.09%. The ex-dividend date of this dividend is Monday, June 29th.
View Amdocs' dividend history.

Amdocs issued an update on its third quarter earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of $1.00 to $1.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $990 million to $1.040 billion, compared to the consensus revenue estimate of $1.05 billion.

5 Wall Street analysts have issued 1 year target prices for Amdocs' stock. Their forecasts range from $72.00 to $85.00. On average, they anticipate Amdocs' stock price to reach $76.40 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts' price targets for Amdocs.

Press coverage about DOX stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amdocs earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Amdocs.

Amdocs saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,590,000 shares, a drop of 9.1% from the June 30th total of 2,850,000 shares. Based on an average trading volume of 890,300 shares, the days-to-cover ratio is presently 2.9 days. Approximately 1.9% of the shares of the stock are short sold.
View Amdocs' Current Options Chain.

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), EPAM Systems (EPAM), Leidos (LDOS), Booz Allen Hamilton (BAH), Gartner (IT), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AbbVie (ABBV), Comcast (CMCSA), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Home Depot (HD), Intel (INTC), Pfizer (PFE), Verizon Communications (VZ) and Cisco Systems (CSCO).

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Amdocs' stock is owned by many different institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (1.32%), First Trust Advisors LP (0.82%), Wedge Capital Management L L P NC (0.63%), CWM LLC (0.41%), PGGM Investments (0.32%) and Harel Insurance Investments & Financial Services Ltd. (0.24%).

DOX stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC, Robeco Institutional Asset Management B.V., Raymond James & Associates, Grandfield & Dodd LLC, Stone Ridge Asset Management LLC, Envestnet Asset Management Inc., Brinker Capital Inc., and CENTRAL TRUST Co.

DOX stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, CWM LLC, UNIVEST FINANCIAL Corp, Exane Asset Management, Anderson Fisher LLC, Sciencast Management LP, Cambiar Investors LLC, and NN Investment Partners Holdings N.V..

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DOX stock can currently be purchased for approximately $62.58.

Amdocs has a market capitalization of $8.43 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

The official website for Amdocs is www.amdocs.com.

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]